Skip to Main Content

Alnylam Pharmaceuticals, Inc. Securities Fraud Class Action

View Complaint
COMPANY         Alnylam Pharmaceuticals, Inc.
COURT United States District Court for the District of Massachusetts
CASE NUMBER 18-cv-12433
JUDGE The Hon. Nathaniel M. Gorton
CLASS PERIOD September 20, 2017 - September 12, 2018

Case Background:

On September 26, 2018, the initial complaint in this securities class action was filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”), and certain of Alnylam’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities class action lawsuit brought on behalf of all persons or entities who purchased or otherwise acquired the securities of Alnylam from September 20, 2017 through September 12, 2018, both dates inclusive (the “Class Period”). 

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

On July 3, 2019, Lead Plaintiffs filed an amended complaint (the “Amended Complaint). Defendants filed a Motion to Dismiss the Amended Complaint on July 31, 2019. On March 23, 2020, the Court issued an Order granting Defendants' Motion to Dismiss. On June 1, Lead Plaintiffs requested permission from the Court to amend the Amended Complaint.  Defendants’ opposed Lead Plaintiffs’’ request.  On March 12, 2021, the Court issued an Order denying Plaintiffs’ Motion to Amend the Amended Complaint.   This action has concluded.  

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) securities between between September 20, 2017 and September 12, 2018, both dates inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at, or you may click here to print a PDF of this form.

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Alnylam Pharmaceuticals, Inc. (2018) prior to the Class Period?
Are you a current or former employee of Alnylam Pharmaceuticals, Inc. (2018)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email